Company / Working Capital
Abbott Laboratories Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$9.5B
FY2025
5-year range
$8.8B / $11.1B
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#4 of 160
Health Care
What the data says
Among 160 Health Care companies, Abbott Laboratories is in the top 2% for working capital. Working Capital has fluctuated over the past 10 years, ranging from $4.8B in FY2019 to $20.1B in FY2016.
Based on SEC 10-K filings.
$9.5B in FY2025 with a 5-year CAGR of +2.2%. Top quartile in the Health Care sector.
Improved from $8.8B to $9.5B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -0.8%
- 5-Year CAGR
- +2.2%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 160This company $9.5B Sector average $757.1M
▼
+1154.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.2%, indicating consistent growth.
- In FY2025, working capital increased 0.0% year-over-year.
- Ranks #4 out of 160 companies in the Health Care sector.
- Peak working capital was recorded in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5B | +0.0% |
| FY2024 | $9.5B | +7.6% |
| FY2023 | $8.8B | -9.3% |
| FY2022 | $9.7B | -12.6% |
| FY2021 | $11.1B | +30.5% |
| FY2020 | $8.5B | +77.6% |
| FY2019 | $4.8B | -14.5% |
| FY2018 | $5.6B | -50.0% |
| FY2017 | $11.2B | -44.1% |
| FY2016 | $20.1B | +304.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026